AssayIndex
Contributing laboratory

PeptideMeter

Runs dual-wavelength detection as standard and reports named related substances rather than totals only. 1,107 reports in the index — 16.5 % of the total.

1,107 reportsgradient 28 minHigh-resolution MSrepeatability 0.22 pp
Section 1

Identification and method basis

Laboratory
PeptideMeter
Short code in this index
PeptideMeter
Location
Tallinn, Estonia
Founded
2021
Reports contributed
1,107
Share of index
16.5%
Purity gradient
28min
Mass resolution
High resolution (ESI-TOF / QTOF)
Stated turnaround
4–8 business days
Measured offset vs reference
-0.024 pp
Within-lab repeatability
0.22pp

PeptideMeter's distinguishing practice is that it reports related substances by name, with retention times, rather than reporting a total impurity figure. For the index this is disproportionately valuable: a named impurity table is what makes the impurity-reconciliation check on each report meaningful, and it is what allows two batches from different suppliers to be identified as the same bulk from their impurity fingerprints. Twenty-nine such cross-links exist in the index and all but four were established from PeptideMeter data.

Dual-wavelength detection at 214 nm and 280 nm is also standard here, which matters for compounds containing tryptophan or tyrosine: the 280 nm trace distinguishes an aromatic impurity from a non-aromatic one without requiring MS, and it makes oxidation products easier to assign.

Measured bias against the reference is −0.05 pp with 95 % limits of agreement of ±0.44 pp, on 214 paired comparisons. That is statistically indistinguishable from zero and the index treats PeptideMeter and Janoshik results as directly comparable.

Section 2

Methods offered

What a laboratory can measure decides what a record can establish. A submission that orders only purity produces a record that names nothing.

  • RP-HPLC purity (%area, 214 nm and 280 nm)
  • LC-MS identity (ESI-QTOF)
  • related-substances profiling with named impurities
  • Karl Fischer water
  • peptide content by amino-acid analysis
Section 3

What this laboratory has measured

Reports 1,107
Median purity reported 98.96% n=1104
Index median 98.99% n=6722
Batches touched 652
0479414192.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=195.75–96.00 %: n=196.00–96.25 %: n=196.25–96.50 %: n=096.50–96.75 %: n=596.75–97.00 %: n=697.00–97.25 %: n=1497.25–97.50 %: n=2297.50–97.75 %: n=4897.75–98.00 %: n=6498.00–98.25 %: n=7298.25–98.50 %: n=9198.50–98.75 %: n=10398.75–99.00 %: n=14199.00–99.25 %: n=13799.25–99.50 %: n=13299.50–99.75 %: n=10199.75–100.00 %: n=165median 98.96 Purity (% area) Reports
Figure 1. Distribution of purity figures reported by PeptideMeter. This is not a distribution of material quality — it is a distribution of what this laboratory was sent, which is a different and unrepresentative sample. Compare its shape against another laboratory's rather than its position: a short gradient compresses the left tail because unresolved species are counted into the main peak.
Compound classReportsMedian purityMethod suitability
Incretin analogues and co-agonists40298.67ADEQUATE
Tissue-repair and immunomodulatory peptides22499.16ADEQUATE
Growth-hormone axis peptides16598.83ADEQUATE
Melanocortin-receptor peptides8299.27ADEQUATE
Neuroactive and cognitive peptides6699.25ADEQUATE
Metabolic and mitochondrial peptides5299.43ADEQUATE
Non-peptide adjuncts5199.15ADEQUATE
Short bioregulator peptides3999.08ADEQUATE
Hypothalamic and posterior-pituitary hormones2699.41ADEQUATE
Most-tested compounds hereReportsMedian purity
Semaglutide14198.85
BPC-15711198.94
Tirzepatide10498.55
Retatrutide8998.30
TB-5005999.44
Melanotan II3599.23
Ipamorelin3399.28
PT-141 (Bremelanotide)3199.24
Semax3199.25
CJC-1295 (no DAC)2498.53
MK-677 (Ibutamoren mesylate)2499.16
Liraglutide2299.25
CJC-1295 with DAC2198.87
L-Glutathione (reduced)2098.78
MOTS-c2099.30
SS-31 (Elamipretide)1999.61
Section 4

Agreement with the other laboratories

Each row is a paired analysis: batches where this laboratory and another one both assayed the same physical lot. A difference on a matched pair is bias plus noise, and it is the only clean way to compare laboratories.

AgainstPaired lotsMean difference (pp)95 % limits of agreementWithin 0.5 pp
Janoshik569-0.024-0.70 to 0.6586%
Medutest362-0.106-0.98 to 0.7771%
VendorInvestigate272+0.451-0.42 to 1.3254%
Nordanalyt244-0.020-0.82 to 0.7877%
Kestrel230-0.413-1.46 to 0.6355%

Positive means PeptideMeter read higher. The full paired analysis, with its assumptions →

Section 5

Provenance of what this laboratory receives

A laboratory that mostly receives supplier-supplied samples produces a record set with a known upward pressure on it, however good its analysis is. This is a property of the submission channel and not of the laboratory.

ProvenanceReportsShareEvidentiary weight
Buyer-sourced766.9%Strongest available evidence in this index.
Supplier-supplied98388.8%Weaker evidence. Read with the caveat below.
Laboratory-retained484.3%Provenance documented, selection uncontrolled.
Section 6

Recent records from this laboratory

The 25 most recent of 1,107. All records from PeptideMeter →
ReportCompoundSupplierLotQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-043106TirzepatideKPKP-2608-D59212026-Q398.905.45105.4Supplier-supplied2MARGINAL
AX-2026-041767SemaglutideFGPFGP-2602-M15082026-Q398.652.54—Supplier-supplied2FAIL
AX-2026-041741TirzepatideFGPFGP-2603-L97142026-Q398.622.57—Supplier-supplied1MARGINAL
AX-2026-041380BPC-157WWBWWB-2606-H39062026-Q399.454.52—Supplier-supplied1MARGINAL
AX-2026-041383BPC-157WWBWWB-2606-H39062026-Q399.174.8491.2Supplier-supplied1MARGINAL
AX-2026-043111TirzepatideKPKP-2608-D59212026-Q399.715.15—Supplier-supplied2MARGINAL
AX-2026-042194RetatrutideHomopeptideHOMO-2605-V98332026-Q398.904.0798.8Supplier-supplied3MARGINAL
AX-2026-041936SemaglutideTFCTFC-2604-X43012026-Q398.624.30—Buyer-sourced1MARGINAL
AX-2026-041482PT-141 (Bremelanotide)QYBQYB-2607-L56152026-Q399.413.97—Supplier-supplied0PASS
AX-2026-041457RetatrutideQYBQYB-2604-B56602026-Q398.662.85102.2Supplier-supplied1MARGINAL
AX-2026-042651Melanotan IIGGPepsGGPE-2603-P87352026-Q399.537.0490.7Supplier-supplied4MARGINAL
AX-2026-041730CJC-1295 with DACQSCQSC-2602-E94742026-Q398.796.9395.4Supplier-supplied1MARGINAL
AX-2026-042547SurvodutideERPERP-2605-E76822026-Q398.255.4493.0Supplier-supplied1MARGINAL
AX-2026-042739SelankGGPepsGGPE-2603-J97082026-Q399.039.09102.1Supplier-supplied0PASS
AX-2026-043086IpamorelinKPKP-2606-D58872026-Q398.743.4591.6Supplier-supplied1FAIL
AX-2026-042215LL-37HomopeptideHOMO-2602-G12802026-Q399.835.3689.9Supplier-supplied1MARGINAL
AX-2026-041489PT-141 (Bremelanotide)QYBQYB-2607-L56152026-Q399.404.3990.1Supplier-supplied0PASS
AX-2026-043502BPC-157BCHBCH-2603-G64222026-Q397.724.86—Buyer-sourced1FAIL
AX-2026-042238IGF-1 LR3HomopeptideHOMO-2607-P12462026-Q398.346.3895.0Laboratory-retained0PASS
AX-2026-041938SemaglutideTFCTFC-2604-X43012026-Q399.064.17—Supplier-supplied0PASS
AX-2026-041925TB-500JEEPJEEP-2605-M48742026-Q399.932.15—Supplier-supplied2MARGINAL
AX-2026-041958TirzepatideTFCTFC-2605-G51342026-Q398.176.5493.0Supplier-supplied3FAIL
AX-2026-042070SS-31 (Elamipretide)TFCTFC-2604-Y74722026-Q398.093.6097.9Supplier-supplied1FAIL
AX-2026-041651LiraglutideQSCQSC-2605-W86022026-Q399.325.96—Supplier-supplied2FAIL
AX-2026-043288L-CarnosineCPCCPC-2603-G16512026-Q399.039.94105.1Supplier-supplied1MARGINAL